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Abstract
Oxytocin and its receptor are synthesised in the heart and blood vessels but effects of
chronic activation of this peripheral oxytocinergic system on cardiovascular function are not
known. In acute studies, systemic administration of low dose oxytocin exerted a protective,
preconditioning effect in experimental models of myocardial ischemia and infarction. In this
study, we investigated the effects of chronic administration of low dose oxytocin following
angiotensin II-induced hypertension, cardiac hypertrophy and renal damage. Angiotensin II
(40 μg/Kg/h) only, oxytocin only (20 or 100 ng/Kg/h), or angiotensin II combined with oxyto-
cin (20 or 100 ng/Kg/h) were infused subcutaneously in adult male Sprague-Dawley rats for
28 days. At day 7, oxytocin or angiotensin-II only did not change hemodynamic parameters,
but animals that received a combination of oxytocin and angiotensin-II had significantly ele-
vated systolic, diastolic and mean arterial pressure compared to controls (P < 0.01). Hemo-
dynamic changes were accompanied by significant left ventricular cardiac hypertrophy and
renal damage at day 28 in animals treated with angiotensin II (P < 0.05) or both oxytocin
and angiotensin II, compared to controls (P < 0.01). Prolonged oxytocin administration did
not affect plasma concentrations of renin and atrial natriuretic peptide, but was associated
with the activation of calcium-dependent protein phosphatase calcineurin, a canonical sig-
nalling mechanism in pressure overload-induced cardiovascular disease. These data dem-
onstrate that oxytocin accelerated angiotensin-II induced hypertension and end-organ renal
damage, suggesting caution should be exercised in the chronic use of oxytocin in individu-
als with hypertension.
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Introduction
Recent advances indicate that oxytocin (OT) is potentially a useful therapeutic agent for many
neuropsychiatric conditions including autism, social anxiety, postnatal depression, obsessive-
compulsive problems and schizophrenia [1, 2]. However, the vast majority of studies on the
putative use of OT as a therapeutic agent have been based on a wide range of single or short-
term OT doses in normal individuals and thus failed to determine how acute and chronic OT
administration differ, and how the therapeutic effects of OT in normal individuals may trans-
late to patients with comorbidities of brain disorders and other systemic disease conditions [3].
The oxytocinergic system influences physiological functions in many organ systems outside
the central nervous system. OT is synthesised in the heart and the OT receptor similar to that
found in the uterus and brain was identified in mammalian cardiac myocytes, cardiac fibro-
blasts and blood vessels [4, 5]. The first cardiac specific role of OT was demonstrated by its
ability to trigger the release of atrial natriuretic peptide (ANP) from mammalian hearts [6],
causing natriuresis and a decrease in blood pressure [7]. Similarly, OT is associated with a
direct, centrally mediated regulation of autonomic outflow to the heart leading to negative ino-
tropic and chronotropic effects [8, 9]. In experimental models of ischemic cardiac injury, single
sub-pressor doses (25–125 ng/Kg) of OT significantly reduced myocardial infarct size, improv-
ing left ventricular function by activating cytoprotective intracellular mechanisms including
the stimulation of endothelial nitric oxide synthase-guanylate cyclase, ANP-cyclic guanosine
monophosphate, phosphoinositide 3-kinase and protein kinase B pathways likely via the OT
receptor [10–12]. In the heart, these intracellular signalling mechanisms subserve many benefi-
cial functions including vasodilation, anti-apoptotic and anti-fibrotic effects [10, 13]. It has
also been suggested that the protective effects of OT in myocardial ischemic injury are linked
to ischemic preconditioning [10, 11]. Acute stimulation of the cardiac OT receptor caused the
up-regulation of protein kinase C, which triggers the activation of mitochondrial ATP-depen-
dent potassium channels (mitoKATP) [10, 13]. This elicits cardiac protective effects through
increased potassium ion uptake into the mitochondria, leading to reduced mitochondrial
steady-state matrix volume, respiratory uncoupling and matrix alkalization [14]. Opening of
mitoKATP channels also causes sustained production of reactive oxygen species during the
ischemic period but reduces it following reperfusion thus preventing irreversible opening of
the mitochondrial permeability transition pore [15].
In marked contrast however, the acute short-term and specifically targeted benefits of OT
could be negated leading to unpredictable outcomes if the use of this neuropeptide is prolonged
in chronic cardiovascular conditions such as hypertension and pressure overload-induced car-
diac and renal damage. For instance, in ischemic cardiac injury, a short-term targeted adminis-
tration of OT increased the expression of transforming growth factor-beta1 in the infarct and
was associated with improved cardiac function and decreased mortality [11, 16, 17]. However,
chronically increased transforming growth factor-beta 1 expression causes pathological cardiac
remodelling characterised by hypertrophy, apoptosis and fibrosis [18]. This demonstrates that
possible chronic effects of OT on cardiovascular function cannot be inferred from studies with
acute dosing regimens. Furthermore, activation of the OT receptor is known to increase intra-
cellular calcium concentration mediated by the stimulation of phospholipase C as seen in the
myometrium [19, 20]. In the heart, accumulation of intracellular calcium and the subsequent
activation of calcium dependent calcineurin activity, and its downstream effector, the nuclear
factor of activated T-cells (NFAT) is a hallmark and a critical intracellular signalling conver-
gence point for many pathological conditions, including chronic pressure overload-induced
cardiac hypertrophy and failure, and ischemic injury [21, 22]. Mammalian myometrial cells
and cardiac myocytes share an identical OT receptor [23] but OT treatment appears to
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ameliorate endothelin-1 and Angiotensin II (AngII) mediated NFAT activation, hypertrophy
and apoptosis in neonatal rat cardiac myocytes [24]. While this in vitro study based on neona-
tal cardiac myocytes indicates that OT may attenuate the effects of pressure-overload induced
cardiac hypertrophy and pathology, effects of prolonged OT administration on cardiovascular
health in general, and chronic pressure overload-induced cardiac hypertrophy and end-organ
damage in vivo have not been investigated. We hypothesised that in the presence of a chronic
hypertensive state, prolonged administration of OT may be pathological. Our objective was to
examine effects and putative pathophysiological mechanisms of prolonged administration of
low dose OT in a rodent model of AngII-induced hypertension, cardiac hypertrophy and renal
damage.
Materials and Methods
Chemicals and Reagents
OT was obtained from Bachem (Bubendorf, Switzerland), AngII and all other chemicals were
obtained from Sigma Chemical Company (St. Louis, MO USA). Bioassay reagents for quantifi-
cation of total plasma renin and ANP, and a bioassay kit for extraction and quantification of
myocardial tissue calcium dependent calcineurin activity were obtained from Sapphire Biosci-
ences (NSW, Australia). Implantable mini-osmotic pumps (Model 2004) were obtained from
Alzet (CA, USA).
Animals and experimental design
Male Sprague Dawley rats (8–9 weeks old, 240–350g) were used for this study. Rats were housed
(2–3 animals per cage), at 23°C, 60% humidity on a 14:10 hour light-dark cycle; were fed stan-
dard rat chow and allowed access to water ad libitum. Animal use and all experimental proce-
dures were approved by James Cook University Animal Ethics Committee according to
Australian guidelines for the use and care of laboratory animals (Approval number A2010).
Forty-eight rats were randomly divided into six experimental groups (n = 8 per group) and
starting body weights were recorded (S1 File). The experimental groups consisted of: Control
receiving phosphate buffered saline; Low dose OT (LDOT, 20 ng/Kg/h); High dose OT (HDOT,
100 ng/Kg/h); AngII (40 μg/Kg/h); AngII with LOT and AngII with HDOT. The dose of AngII
was based on that used in previous models of hypertension and cardiac hypertrophy induced by
AngII infusion [25, 26]. The doses of OT were based on those used in acute studies utilising OT
infusion in myocardial infarction [11]. AngII and OT were dissolved in phosphate buffered saline
and treatments were administered for 28 days via subcutaneously implanted mini-osmotic
pumps. One animal in the AngII only group died suddenly of an unidentified cause before the
conclusion of experiments but this did not warrant any changes in the experimental design.
Osmotic pump implantation
Mini-osmotic pumps were prepared as per manufacturer's instructions. Rats were anaesthe-
tised with isoflurane (5% induction, 2% maintenance, at a flow rate of 2 L/min in oxygen) and
an incision approximately 1 cm in diameter was made between the scapulae and pumps were
inserted into the incision. Once surgery was completed, wounds were closed using 5.8 mm sur-
gical staples and swabbed with 7.5% w/v iodine to prevent contamination and infection.
Hemodynamic measurements
Baseline diastolic, systolic and mean arterial blood pressures, and heart rate were measured
immediately prior to pump implantation and at day 7 and day 28 after commencement of the
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experiment. Animals were acclimatized to the restraint apparatus on a heated pad at 37.5°C in
a quiet environment under light isoflurane-induced anaesthesia (4% induction, 2% mainte-
nance, at a flow rate of 2 L/min in oxygen). Measurements were taken using a computerised
CODA blood pressure monitor (Kent Scientific, CT USA), equipped with an occlusion cuff
and a volume pressure recording sensor. Values were recorded until five complete measure-
ments were obtained without the range of the five replicate mean arterial pressures exceeding
15mmHg. All blood pressure measurements were taken between the hours of 6:00 AM-11:00
AM to minimise the impact of diurnal variation. This method has been validated and shown to
have good reproducibility and accuracy over the physiological range of blood pressure values
in rodents [27].
Echocardiography
Echocardiograms (M-mode) were obtained 21 days after pump implantation (n = 7–8 per
group), under light isoflurane-induced anaesthesia as described above. Rats were positioned
right side down on a heated pad and echocardiograms were obtained via the right parasternal
short axis view just below the level of the mitral valve using a curved array (3–9 Mhz) probe on
a MyLab70 XVision Esaote
1
ultrasound machine. Left ventricular mass was calculated using
the American Society of Echocardiography formula in Eq (1) below and then corrected for var-
iations in body weight where 1.04 is the specific gravity of muscle, LVIDd is the left ventricular
internal diameter in diastole, IVSd is the interventricular septal diameter in diastole and
LVPWd is the left ventricular posterior wall thickness in diastole.
1:04½ðIVSdþ LVIDdþ LVPWdÞ3  ðLVIDdÞ3 Eqð1Þ
Fractional shortening (FS) was calculated according to Eq (2), where LVIDS is the left ven-
tricular internal diameter in systole and LVIDd is the left ventricular internal diameter in dias-
tole.
ðLVIDd  LVIDsÞ =ðLVIDdÞ  100 Eqð2Þ
For each measured parameter, an average of five cardiac cycles was used by a veterinary
echocardiologist who was blinded to the experimental treatment regimens.
Histological and morphometric analysis of cardiac hypertrophy and renal
damage
At day 28, animals were sacrificed by carbon dioxide asphyxiation. Hearts were fixed in diastole
by a retrograde apical infusion of 1% potassium chloride, rapidly removed, blot dried, weighed
and cut in half along the cross sectional plane. The basal half of the heart and the left kidney
were fixed in 10% neutral buffered formalin and embedded in paraffin for histological analysis.
Sections of the heart and kidney (5μm) were prepared and stained with hematoxylin and eosin,
and Masson’s trichrome, and then photographed under a bright-field with a microscope
(Olympus BX43F). Collagen deposition in the posterior wall of the left ventricle and the inter-
ventricular septal wall was analysed using Image-J software (NIHealth, MD USA), according to
previously described methods [28]. For kidney sections, a histological scoring system based on
a semi-quantitative analysis of pathological changes [29] was also used to assess AngII or OT
induced changes in a single-blinded manner. Assessed parameters included: glomerular necro-
sis, tubular degeneration, necrosis and epithelial sloughing, vascular congestion and extravasa-
tion, and interstitial fibrosis. The grading system used to assess these pathological changes was
based on 0–4 score designed by a pathologist who was blinded to the treatments and was out-
lined as, 0 = normal with no noticeable histopathological changes; 1 = minor: 0–29%;
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2 = moderate: 30–49%; 3 = marked: 50–69% and 4 = severe: 70–100%. Six individual samples
were analysed for each of the six experimental groups and histological scores were reported as
mean ± standard error of the mean (SEM).
Quantifying plasma electrolytes, creatinine, urea, ANP and prorenin/
renin
At day 28, rats were euthanized by carbon dioxide overdose, blood was collected in heparinised
tubes and plasma samples (n = 6 per experimental group) were collected by centrifugation at
2000 xg, for 15 min at 4°C and then stored at -20°C prior to analysis. Photometric analysis was
performed to determine plasma sodium, potassium, chloride, calcium, magnesium, phosphate,
bicarbonate, urea, creatinine, total protein and glutamate dehydrogenase activity using a chem-
istry analyser (Beckman, AU480). Urea to creatinine ratio was calculated as an indicator for
renal failure. Urine flow rate was not measured in this study but an indirect measure of creati-
nine clearance (mL/min) was used according to a method that utilises plasma creatinine con-
centration and body mass index in rats [30], using Eq (3).
CrðmL = minÞ ¼ 220 103ðmmol =min = kgÞ  weightðkgÞ  ½Crðmmol =LÞ1 ð3Þ
Where Cr is plasma creatinine concentration.
Total plasma prorenin/renin concentration was determined using an ELISA assay kit,
according to the manufacturer’s instructions (Molecular Innovations) and plasma ANP was
quantified by using an ANP ELISA kit [31].
Calcineurin activity
Frozen heart tissue was thawed and a section of the left ventricle (0.20–0.35g) was isolated and
homogenised using a Polytron (Brinkmann PT2100) tissue homogeniser in lysis buffer con-
taining 50 mmol/L Tris (pH 7.5), 0.1 mmol/L EDTA, 0.1 mmol/ L EGTA, 0.2% NP-40, 1
mmol/ L DTT, 100 μmol/ L PMSF, 5 mmol/L ascorbic acid, and protease inhibitor cocktail.
The tissue homogenate was centrifuged at 18000 xg for 30 min at 4°C and the supernatant was
desalted to remove excess phosphate and nucleotides. Calcineurin activity was measured by the
rate of dephosphorylation of a synthetic peptide using a calcineurin assay kit according to the
manufacturer’s instructions. The released free phosphate was detected using the standard Mal-
achite green colorimetric assay [32]. Relative calcineurin phosphatase activity was expressed as
pmol phosphate/μg of protein.
Statistical Analysis
Normally distributed data were presented as means ± SEM and analysed using one-way analy-
sis of variance with Tukey's post-hoc tests for multiple comparisons. Data that were not consis-
tent with a Gaussian distribution were presented as medians with the interquartile range (IQR)
and analysed using the Kruskal-Wallis test paired with Dunn’s post-hoc test for multiple com-
parisons and the linear mixed effects model to adjust for unequal variance between experimen-
tal groups [33]. Changes were considered significant at P< 0.05.
Results
Chronic Administration of Oxytocin Accelerated Angiotensin II-induced
Hypertension
Blood pressure and heart rate was measured immediately before pump implantation (day 1)
and after 7 and 28 days of OT, AngII or AngII and OT infusion. Administration of only OT at
Oxytocin and Angiotensin II-Induced Pathology
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20 ng/kg/h (LDOT) or 100 ng/kg/h (HDOT) had no effect on any of the measured hemody-
namic parameters after 28 days of treatment. At day 7 however, systolic and diastolic blood
pressure, and mean arterial pressure was significantly elevated in animals that received both
OT and AngII but not AngII only (Figs 1 and 2). Median systolic blood pressure (mmHg) for
animals receiving both LDOT and AngII was 151 (146–163) versus control: 100 (98–103);
P< 0.05. Diastolic pressure and mean arterial pressure values (mmHg) were 102 (99–112)
[LDOT and AngII] versus 68 (67–68) [control; P< 0.05], and 116 (112–131) [LDOT and
AngII] versus 76 (75–79) [control; P< 0.05] respectively. Similarly, a significant increase in
systolic, diastolic and mean arterial pressure was observed in animals receiving a combination
of AngII and HDOT (P< 0.05), but no difference was observed between animals receiving
AngII and LDOT, and AngII and HDOT.
At day 28, following the administration of AngII only, AngII and LDOT or AngII and
HDOT, a significant increase in systolic, diastolic and mean arterial pressure was observed
(Figs 1 and 2). Median arterial pressure values (mmHg) were 85 (79–88) [control] versus 99
(90–129) [AngII only; P< 0.05], 112 (99–152) [AngII and LDOT; P< 0.05] and, 128 (114–
140) [AngII and HDOT; P< 0.01]. The hypertensive effects resulting from administration of a
combination OT and AngII at day 7 were sustained at day 28 but the administration of AngII
Fig 1. Effects of oxytocin and angiotensin II on systolic and diastolic blood pressure. Systolic and diastolic blood pressure (mmHg) after 1, 7 and 28
days of subcutaneous infusion of saline (control), low dose oxytocin (LDOT), high dose oxytocin (HDOT), angiotensin II (AngII), a combination of angiotensin
II and low dose oxytocin (AngII + LDOT) or angiotensin II and high dose oxytocin (AngII + HDOT). Data represent medians with interquartile range (n = 5–8).
Asterisks (*) indicate significant difference from the control group on the same day (* P<0.05, ** P<0.01). Clear bars represent saline, low dose oxytocin
(LDOT) or high dose oxytocin (HDOT) controls, and filled bars represent angiotensin II, or a combination of angiotensin II and low or high dose oxytocin.
doi:10.1371/journal.pone.0138048.g001
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together with LDOT or HDOT did not cause a significant change in blood pressure compared
to the AngII only group. A significant increase in blood pressure between day 7 and day 28 was
only observed in the AngII group (P< 0.05). There were no significant differences in heart
rates between any of the treatment groups at day 1, 7 or 28 (Fig 2).
Effects of Oxytocin on Angiotensin II-Induced Cardiac Hypertrophy and
Fibrosis
Chronic pressure overload leads to cardiac hypertrophy, cardiomyocyte apoptosis and fibrosis
[18]. We assessed effects of OT on AngII induced cardiac hypertrophy and fibrosis. Wet heart
weights were measured and normalised to body weight for comparison between treatment
groups. Heart weight to body weight ratio was significantly elevated (P< 0.05), only in animals
that were administered a combination of AngII and LDOT or AngII and HDOT (Fig 3). Mean
heart to body weight ratios (mg/kg) were Control: 3.2 ± 0.2; LDOT only: 3.4 ± 0.7; HDOT
only: 3.1 ± 0.1; AngII only: 3.7 ± 0.4; AngII and LDOT: 3.9 ± 0.5; AngII and HDOT: 4.0 ± 0.4.
Fig 2. Effects of oxytocin and angiotensin II on mean arterial pressure and heart rate.Mean arterial blood pressure (mmHg) and heart rate (beats/min)
after 1, 7 and 28 days of subcutaneous infusion of saline (control), low dose oxytocin (LDOT), high dose oxytocin (HDOT), angiotensin II (AngII), a
combination of angiotensin II and low dose oxytocin (AngII + LDOT) or angiotensin II and high dose oxytocin (AngII + HDOT). Data represent medians with
interquartile range (n = 5–8). Asterisks (*) indicate significant difference from the control group on the same day (* P<0.05, ** P<0.01). Clear bars represent
saline, low dose oxytocin (LDOT) or high dose oxytocin (HDOT) controls, and filled bars represent angiotensin II, or a combination of angiotensin II and low or
high dose oxytocin.
doi:10.1371/journal.pone.0138048.g002
Oxytocin and Angiotensin II-Induced Pathology
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Left ventricular mass index (mg/g) as determined by echocardiography was significantly higher
in animals treated with AngII only, AngII and LDOT and, AngII and HDOT compared to the
control group. The indices for left ventricular mass (mg/g) were 1.9 ± 0.3 [control] versus
2.5 ± 0.4 [AngII only; P< 0.05], 2.5 ± 0.5 [AngII and LDOT; P< 0.05] and 2.7 ± 0.5 [AngII
and HDOT; P< 0.01]. Interventricular septal thickness during diastole and systole was signifi-
cantly higher only in animals receiving AngII and HDOT compared to control (P< 0.05) but
there were no changes in all the other indices of cardiovascular function including percentage
FS and ejection fraction in any of the groups (Table 1). Similarly, there were no significant dif-
ferences in collagen deposition in the posterior wall of the left ventricle and the interventricular
septal wall between any of the treatment groups (S2 File).
Fig 3. Effects of oxytocin on angiotensin II-induced cardiac hypertrophy. Representative hematoxylin and eosin stained histological sections of the
interventricular septal wall of the heart (original magnification x400) showing changes in cardiac myocyte size, left ventricular mass and heart to body weight
ratio. Left ventricular mass index and heart weight were quantified at day 21 and 28 respectively following the infusion of saline (control), low dose oxytocin
(LDOT), high dose oxytocin (HDOT), angiotensin II (AngII), a combination of angiotensin II and low dose oxytocin (AngII + LDOT) or angiotensin II and high
dose oxytocin (AngII + HDOT). Data on bar graphs represent mean ± SEM (n = 6–8). Asterisks (*) indicate significant difference from the control group (*
P<0.05, ** P<0.01).
doi:10.1371/journal.pone.0138048.g003
Oxytocin and Angiotensin II-Induced Pathology
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Oxytocin Exacerbated Angiotensin II-induced Renal Damage
Kidneys are susceptible to the deleterious effects of chronic hypertension. Effects of OT on
AngII-induced hypertension and renal, end-organ damage were assessed by histological evalu-
ations as well as the analysis of plasma urea and creatinine as indicators of renal function. At
day 28, plasma urea and creatinine concentrations were significantly elevated only in animals
that were treated with both AngII and OT (Table 2 and Fig 4). Mean urea to creatinine plasma
concentration ratios were Control: 278 ± 16 versus AngII only: 309 ± 17; AngII and LDOT:
350 ± 16, P< 0.05; AngII and HDOT: 339 ± 27, P< 0.05. The marked increase in plasma urea
and creatinine concentration was matched by a corresponding, significant decrease in creati-
nine clearance in animals that received both AngII and LDOT or Ang II and HDOT (Fig 4).
Mean creatinine clearance values (mL/min) were 4.4 ± 0.2 [Control] versus 3.1 ± 0.4 [AngII
only], 2.5 ± 0.4 [AngII and LDOT; P< 0.01] and, 2.7 ± 0.3 [AngII and HDOT; P< 0.01]. Sig-
nificant renal damage (P< 0.05) was also evident on Masson’s trichrome stained histological
sections of kidneys from animals that received AngII only, and a combination of AngII and
LDOT or AngII and HDOT (Fig 4 and S3 File). Observed pathological effects included tubular
Table 1. Echocardiographic Evaluations of Left Ventricular Dimensions and Function.
Control LDOT HDOT AngII AngII + LDOT AngII + HDOT
IVSs (mm) 2.13 ± 0.10 2.40 ± 0.12 2.18 ± 0.13 2.35 ± 0.20 2.44 ± 0.16 2.76 ± 0.10*
IVSd (mm) 1.36 ± 0.10 1.22 ± 0.07 1.45 ± 0.12 1.57 ± 0.12 1.65 ± 0.13 1.90 ± 0.15*
LVIDs (mm) 4.95 ± 0.22 4.96 ± 0.23 5.13 ± 0.12 4.37 ± 0.46 4.33 ± 0.25 4.29 ± 0.30
LVIDd (mm) 7.33 ± 0.39 7.49 ± 0.39 7.46 ± 0.16 6.68 ± 0.28 6.79 ± 0.20 6.67 ± 0.29
PWs (mm) 2.70 ± 0.15 3.14 ± 0.13 2.63 ± 0.19 2.83 ± 0.18 2.90 ± 0.14 2.77 ± 0.17
PWd (mm) 2.08 ± 0.18 2.35 ± 0.10 1.90 ± 0.14 2.20 ± 0.22 2.05 ± 0.27 2.00 ± 0.12
FS (%) 32.3 ± 1.4 33.0 ± 1.9 31.4 ± 1.6 35.2 ± 4.5 36.3 ± 3.0 35.4 ± 2.4
EF (%) 66.1 ± 1.8 68.6 ± 2.9 64.6 ± 2.3 68.7 ± 6.1 70.9 ± 4.3 70.6 ± 3.0
Data represent the mean ± SEM, n = 7–8 per group. Asterisks (*) and bold indicate significant difference compared with control (P < 0.05). LDOT, low
dose oxytocin; HDOT, high dose oxytocin; AngII, angiotensin II; IVSs, interventricular septum thickness during systole; IVSd, interventricular septum
thickness during diastole; LVIDs, left ventricular internal diameter during systole; LVIDd, left ventricular internal diameter during diastole; PWs, left ventricle
posterior wall thickness during systole; PWd, left ventricle posterior wall thickness during diastole; FS, fractional shortening; EF, ejection fraction.
doi:10.1371/journal.pone.0138048.t001
Table 2. Effects of oxytocin and angiotensin II on plasma urea and creatinine concentrations, and plasma electrolytes and osmolality.
Control LDOT HDOT AngII AngII + LDOT AngII + HDOT
Urea (mM) 6.6 ± 0.5 6.2 ± 0.3 6.6 ± 0.3 9.2 ± 1.3 13.5 ± 2.3* 15.1 ± 1.9**
Creatinine (mM) 0.02 ± 0.001 0.03 ± 0.001 0.03 ± 0.001 0.03 ± 0.001 0.04 ± 0.001* 0.04 ± 0.001*
Albumin (mg/mL) 65 ± 1 65 ± 1 67 ± 1 60 ± 1 68 ± 2 64 ± 1
Na+ (mM) 143 ± 1 143 ± 1 144 ± 1 143 ± 1 140 ± 2 142 ± 1
K+ (mM) 7.2 ± 0.6 6.4 ± 0.1 7.2 ± 0.2 5.8 ± 0.4 6.2 ± 0.4 6.6 ± 0.2
Ca2+ (mM) 2.9 ± 0.1 2.9 ± 0.03 3.0 ± 0.1 2.8 ± 0.1 3.0 ± 0.1 2.9 ± 0.1
Cl- (mM) 97 ± 1 97 ± 1 97 ± 1 96 ± 2 91 ± 2 92 ± 2
PO4
2- (mM) 3.5 ± 0.2 3.1 ± 0.1 3.3 ± 0.1 3.0 ± 0.2 3.2 ± 0.2 3.2 ± 0.3
HCO3
- (mM) 33 ± 2 33 ± 1 34 ± 1 34 ± 2 35 ± 1 36 ± 2
Osmolality (mM) 292 ± 2 293 ± 2 294 ± 2 296 ± 1 294 ± 1 294 ± 1
Data represent mean ± SEM, n = 5–6 per group, asterisks (*) and bold indicate significant difference from control group (* P<0.05, ** P<0.01). LDOT, low
dose oxytocin; HDOT, high dose oxytocin; AngII, angiotensin-II.
doi:10.1371/journal.pone.0138048.t002
Oxytocin and Angiotensin II-Induced Pathology
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epithelial cell necrosis and desquamation, vacuolisation and degeneration of basement mem-
branes, luminal congestion with loss of brush borders, enlargement of Bowman's cavities and,
interstitial fibrosis (Fig 4 and S3 File). Histological scores were: 1.2 ± 0.3 in AngII treated ani-
mals, 2.1 ± 0.4 in animals that received Ang II and LDOT and 1.7 ± 0.3 in animals that received
AngII and HDOT(Fig 4 and S3 File). No noticeable pathological effects were observed in the
control, LDOT or HDOT groups.
Effects of Chronic Oxytocin Administration on Plasma Atrial Natriuretic
Peptide and Renin Concentration
ANP and renin are important blood pressure regulating factors secreted from the heart and
kidneys respectively. In the current study we investigated whether the hypertensive effects
resulting from chronic administration of AngII and OT were attributed to sustained changes in
circulating levels of ANP and renin. Plasma samples obtained after 28 days of AngII or AngII
Fig 4. Effects of oxytocin on angiotensin II-induced renal damage. Representative Masson’s trichrome stained histological sections of the renal cortex
and medulla showing effects of oxytocin on angiotensin II induced renal damage. Pathological changes in the kidney were assessed by histological
evaluation of glomerular necrosis, tubular degeneration, necrosis and epithelial sloughing and interstitial fibrosis (‡), and vascular congestion and
extravasation (†). The original magnification was x100. Changes in renal function due to intra-renal damage were also evaluated as plasma urea to creatinine
ratio and creatinine clearance. Measurements were made 28 days following the infusion of saline (control), low dose oxytocin (LDOT), high dose oxytocin
(HDOT), angiotensin II (AngII), a combination of angiotensin II and low dose oxytocin (AngII + LDOT), or angiotensin II and high dose oxytocin (AngII
+ HDOT). Data represent the mean ± SEM (n = 6) and asterisks (*) on bar graphs indicate significant difference from the control group (* P<0.05, ** P<0.01).
doi:10.1371/journal.pone.0138048.g004
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and OT administration revealed no significant differences in plasma ANP, sodium, potassium
and chloride concentrations between any of the treatment groups (Fig 5 and Table 2). In con-
trast however, total plasma renin and prorenin was significantly decreased (P< 0.05) in all ani-
mals that received AngII (Fig 5). Median plasma renin concentrations (ng/mL) were 30 (17–
41) [Control] versus 6 (4–16) [AngII only; P< 0.05], 5 (5–11) [AngII and LDOT; P< 0.05]
and, 4 (3–5) [AngII and HDOT; P< 0.001].
Effects of Oxytocin on Angiotensin II-Induced Activation of Phosphatase
Calcineurin
Activation of calcineurin, a calcium-calmodulin-activated serine/threonine phosphatase, plays
a critical signal transduction role in the development of pressure overload-induced cardiac
hypertrophy, and renal damage. We investigated effects of chronic OT administration on
AngII induced activation of calcineurin in heart tissue. The increase in calcineurin phosphatase
activity was statistically significant only in animals that received both AngII and, LDOT or
HDOT (Fig 6). Median calcineurin phosphatase activities (pmol phosphate/μg protein) were
11 (8–14) [Control] versus 15 (10–18) [LDOT only], 10 (6–11) [HDOT only], 19 (12–22)
[AngII only], 36 (22–38) [AngII and LDOT; P< 0.01] and, 25 (19–33) [AngII and HDOT;
P< 0.05].
Discussion
The hypothesis tested in this study was that prolonged systemic administration of OT aggra-
vates the adverse effects of chronic hypertension induced by AngII. Our major observations
were that OT accelerated AngII-induced hypertension in a dose dependent manner leading to
Fig 5. Effects of oxytocin and angiotensin II on plasma ANP and renin concentration. Plasma ANP and, prorenin and renin concentrations were
quantified following the administration of saline (control), low dose oxytocin (LDOT), high dose oxytocin (HDOT), angiotensin II (AngII), a combination of
angiotensin II and low dose oxytocin (AngII + LDOT) or angiotensin II and high dose oxytocin (AngII + HDOT) for 28 days. Data represent mean ± SEM
(n = 5). Asterisks (*) indicate significant difference from the control group (* P<0.05, ** P<0.01).
doi:10.1371/journal.pone.0138048.g005
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a compensatory phase of cardiac hypertrophy with increased heart weight and left ventricular
mass; but without significant changes in collagen deposition and myocardial fibrosis, or func-
tion as determined by evaluation of the left ventricular ejection fraction and fractional shorten-
ing. The acceleration of the hypertensive effects of AngII by OT was accompanied by
significant kidney damage and compromised renal function. While the prolonged administra-
tion of OT did not change plasma concentrations of ANP and renin, or plasma osmolality, it
augmented the activation of calcium-dependent protein phosphatase calcineurin, a common
signalling mechanism in pressure overload-induced pathological conditions [21, 22].
Chronic hypertension was induced by the subcutaneous infusion of AngII at 40 μg/kg/h
for 4 weeks and effects of OT were tested by the simultaneous subcutaneous infusion of OT
at 20 ng/kg/h or 100 ng/kg/h for 28 days, to cause chronic oxytocinergic stimulation in
male adult Sprague Dawley rats. In previous studies, modelling of cardiovascular disease in
Sprague Dawley rats has typically used subcutaneously infused AngII at doses between 10 and
30 μg/kg/h. Following the infusion of 10.5 μg/kg/h of AngII, systolic blood pressure was signifi-
cantly elevated by day 14 [25], while at 30 μg/kg/h of AngII infusion, systolic blood pressure
was significantly elevated by day 7 [34]. The dose and route of AngII administration that we
employed in the current study is very comparable to that used by Brink and colleagues [34],
however blood pressure was not significantly elevated by day 7 in this study. The male Sprague
Dawley rats utilised in our study were younger adults (2 versus 5 months old) and this may
have accounted for the delayed development of hypertension. Under these experimental condi-
tions, AngII caused a significant increase in blood pressure by day 28. When the infusion of
Fig 6. Effects of oxytocin and angiotensin II on myocardial calcineurin activity. Activity of the
myocardial calcium-dependent calcineurin phosphatase was quantified following the administration of saline
(control), low dose oxytocin (LDOT), high dose oxytocin (HDOT), angiotensin II (AngII), a combination of
angiotensin II and low dose oxytocin (AngII + LDOT) or angiotensin II and high dose oxytocin (AngII + HDOT)
for 28 days. Data represent mean ± SEM (n = 5). Asterisks (*) indicate significant difference from the control
group (* P<0.05, ** P<0.01).
doi:10.1371/journal.pone.0138048.g006
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AngII was combined with OT in the current study, systolic, diastolic and mean arterial blood
pressure were significantly elevated at day 7 but by day 28 blood pressure was equally elevated
in all animals that received AngII only or AngII and OT. This indicates that hypertension was
attained earlier and therefore prolonged, by combining AngII with OT. The sustained hyper-
tension led to a significant, OT dose-dependent increase in heart weight and left ventricular
mass in animals that received both AngII and OT. These data are in marked contrast with pre-
vious in vitro studies where a comparable, low concentration of OT (100 nmoles/L) mitigated
AngII-induced hypertrophy and apoptosis in neonatal cardiac myocytes by activating cytopro-
tective mechanisms including ANP release, endothelial nitric oxide synthase and guanylate
cyclase stimulation and increasing intracellular cyclic guanosine monophosphate [24]. This
disparity indicates that systemic effects of chronic OT administration may be more complex
and thus difficult to predict based on in vitro or ex vivo studies with acute dosing regimens.
Certainly, even with whole animal studies, OT may increase [35, 36] or decrease [36, 37] blood
pressure and heart rate depending on dosage and route of administration, length of treatment
and, the initial blood pressure status or trigger for hypertension. Here we demonstrate that pro-
longed subcutaneous administration of OT (20–100 ng/kg/h, 28 days) in itself exerts no
changes on heart rate or blood pressure and yet by comparison, intrathecal administration of
equivalent doses of OT into the central nervous system caused transient cardiac sympathetic
activation and tachycardia, and subsequent lowering of blood pressure via OT receptor medi-
ated stimulation of paraventricular nuclei with spinally projecting neurones [38]. The apparent
lack of effect on heart rate in our study may be attributed to the fact that the subcutaneously
administered, low dose range of OT had very limited access to the central nervous system
mainly because of poor blood-brain barrier permeability and unfavourable pharmacokinetic
profiles; this notion is supported by previous studies [39]. It can be argued therefore, that the
sub-pressor dose range of OT used in the current study accelerated the hypertensive effects via
shared peripheral mechanisms with AngII. At a relatively high plasma concentration, akin to
that detected at term pregnancy or during parturition, OT increases blood pressure by activat-
ing the vasopressin V1aR receptor [40]. Similarly, AngII is known to stimulate vasopressin
release in the circulation and this contributes to increase in blood volume, arterial resistance
and elevated blood pressure [41]. It is unlikely however, that involvement of vasopressin and
its receptor would serve as the only mechanism to account for the prohypertensive effects of
OT in the current study. This is partly because OT has very low intrinsic activity at V1aR vasso-
pressin receptors making it difficult to constitute full functionality at the dose range used here
[40]. Opposite hemodynamic challenges associated with hypovolemia and hypotension are
accompanied by increased secretion of OT, and the intravenous infusion of OT (125 ng/kg/h)
over 120 minutes activates an increase in plasma renin concentration by stimulating OT recep-
tors in macula densa cells of the juxtaglomerular apparatus in the kidney of Sprague Dawley
rats [35, 42]. The acute effects of OT on renin release were not re-evaluated in the current
study but they do offer a sound rationale for enhancing the renin-AngII system and therefore
contributing to the accelerated elevation of blood pressure by OT that we observed. With
chronic OT infusion over 28 days however, we observed a significant decrease in total plasma
renin concentrations in all animals that received only AngII or AngII and OT. Moreover, in
animals that received AngII or AngII and OT treatment, the decrease in total plasma renin was
inversely proportional to the elevation in blood pressure at day 7 and 28. This observation is
consistent with a form of negative feedback where the increased stimulation of the AngII type
1 receptors reduces renin release from the kidneys as observed to a similar extent in other stud-
ies using subcutaneous AngII treatment at a similar dose range [43, 44].
The progression of chronic hypertension to cardiac hypertrophy and congestive heart fail-
ure is characterised by an increase in the biosynthesis and release of ANP from the atrial and
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ventricular myocytes and this serves an important protective mechanism contributing to natri-
uresis, increased urine volume and lowering of blood pressure [6, 7, 24]. Plasma ANP was
therefore measured as a biomarker for cardiac hypertrophy [45, 46], as well as to determine
whether OT increased plasma ANP as seen previously [6]. However, when comparable doses
of OT (20 or 100 ng/kg/h) were infused subcutaneously for 28 days in the current study, OT,
AngII, or a combination of AngII and OT had no effect on total plasma ANP, sodium and
potassium concentrations or plasma osmolality. Perhaps this is not surprising because the car-
diac hypertrophy that we observed was in a compensatory phase with no signs of overt failure
and thus would not be predicted to stimulate significant ANP release. These data also suggest
that putative cardiac protective effects of OT in acute conditions such as ischemic reperfusion
injury may not be prominent with the chronic administration of OT. We investigated whether
chronically administered OT may have exacerbated the effects of AngII via pathological mech-
anisms mediated by increased intracellular calcium. Indeed, we confirmed that the administra-
tion of OT and AngII caused significant activation of calcium-dependent protein phosphatase
calcineurin, a canonical early signalling mechanism in pressure overload-induced cardiovascu-
lar disease [21, 22]. This indicates that the cardiac myocyte hypertrophy that we observed with
AngII only or AngII and OT was an early compensatory phase of a pathological effect but not a
normal physiological response.
Kidneys are susceptible to hypertension-induced end-organ damage prompted by reduction
of renal perfusion which triggers cellular injury. In this study we show that the acceleration of
AngII-induced hypertension by OT corroborated the significant renal damage characterised by
tubular epithelial cell necrosis and desquamation, vacuolisation and degeneration of basement
membranes, luminal congestion with loss of brush borders, enlargement of Bowman's cavities
and, interstitial fibrosis. Thus, these effects may be attributed to the prolonged pressor
responses resulting from combining OT and AngII. This is further substantiated by the fact
that a significant increase in plasma urea to creatinine ratio and decreased creatinine clearance
was observed only in animals treated with both AngII and LDOT or HDOT. As the increase in
plasma urea to creatinine ratio and the decrease in creatinine clearance are standard markers
for compromised renal function in clinical pathology, we conclude that chronic OT adminis-
tration exacerbated AngII-induced renal damage. This however, contradicts recent literature
which shows that OT administered at a similar dose of 125 ng/kg/h over 12 weeks, exerted car-
dioprotective effects in leptin receptor deficient (db/db) obese diabetic mice [47]. It was sug-
gested that these changes in db/db mice were partly attributed to decreased body weight gain
and adipocyte size, as well as reduced oxidative stress due to the beneficial effects of OT on car-
bohydrate metabolism [47]. Peripheral OT administration can also reduce appetite in leptin-
receptor deficient rats (fa(k)/fa(k)), and inhibit a decrease in energy expenditure due to weight
loss [48]. The differences between the results of the current study and that of Plante and co-
workers [47], may be due to a number of factors. Firstly, there are prominent species differ-
ences between mice and rats and to a great extent, hypertension and renal damage that is seen
in experimental models in rats is difficult to induce in mice [49]. Secondly, these studies may
collectively suggest that OT is cardioprotective when obesity and diabetes are a major contrib-
uting factor, but is not cardioprotective in models of inappropriate RAAS regulation. Thus, it
could be hypothesised that OT could be beneficial or detrimental to cardiac health depending
on the underlying pathophysiological mechanisms.
Study Limitations
Based on the experimental design and execution of the current study, useful conclusions can be
drawn from the generated data. Nonetheless, there are a few of limitations to this study as
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outlined below. Firstly, only one model of AngII-induced hypertension was used in rats, and a
limited dose range of OT was tested. These observations should be confirmed in other models of
chronic hypertension and other animal species with a relatively larger sample size, a wide OT
dose range, different routes of OT administration and duration. Secondly, the primary observa-
tion of renal damage induced by co-administration of AngII and OT was not confirmed by
assessing changes in glomerular filtration rate directly. This was because of the inability to track
and quantify total urine output due to the limited access to an adequate number of metabolic
cages for rats. Nonetheless creatinine clearance was estimated using a validated method which
correlates very well with glomerular filtration rate in Sprague Dawley rats [30]. Our data indicates
that the compromised creatinine clearance matched the observed renal damage histologically.
Moreover, in animals treated with OT and AngII, the evaluated urea:creatinine ratios (mmol/L:
μmol/L), a standard clinical pathology practice indicates a likelihood of intra-renal damage thus
supporting these conclusions. Thirdly, we did not quantify changes in plasma AngII and OT.
This is partly because subcutaneous infusion of AngII and OT in Sprague Dawley rats has been
previously validated [11, 25, 34], and indeed the observed cardiovascular changes indicate that
our drug infusions exerted the intended effects. In addition, we only took snapshot readings of
blood pressure at day 1, 7 and 28 following OT and AngII infusion. This is a minor limitation as
snapshot readings can still provide important information from which meaningful conclusions
can be drawn. Our results should be confirmed in future studies utilising telemetry probes to
allow for continuous observation of blood pressure. Lastly, detailed mechanisms that underpin
some of the conclusions in the current study remain to be determined. The extensive, complex
and often overlapping interactions between OT, AngII or vasopressin receptors in maintaining
homeostasis in cardiovascular function precluded any meaningful use of receptor antagonist to
elucidate mechanisms, but transgenic or OT receptor gene knockout animal models could be uti-
lized to determine whether the observations in the current study were exclusively mediated by
the OT receptor. Mechanistically we observed that calcineurin activity was elevated in the myo-
cardium coinciding with the accelerated increase in blood pressure in animals that received both
AngII and OT. OT augmented the pathological effects of AngII in the kidneys but kidney specific
activation of calcineurin was not demonstrated. While we have access to formalin fixed kidney
samples from this study, we realise now that the fixed tissues are not suitable for quantifying
renal calcineurin activity and the accompanying downstream biochemical effector pathways.
Thus, the current study presents important primary observations relating to prohypertensive
effects of OT in an AngII infusion model in rats, but additional studies geared at elucidating
detailed molecular mechanisms are warranted.
Perspectives and conclusions
Intranasal administration of OT is in clinical trials for management of some neuropsychiatric
disorders including autism and schizophrenia [2, 3], and a number of studies have indicated
that OT may also serve beneficial roles in experimental models of acute myocardial injury
[10, 12]. However, the characterisation of cardiovascular effects of OT has been based on
acute in vivo or ex vivo studies and effects of chronic activation of the oxytocinergic system
on cardiovascular function are not known. To a great extent, even human clinical trials with
OT have been limited to single or sub-acute dosing regimens in normal individuals or
patients with behavioural or neuropsychiatric disease [2, 3]. To our knowledge, the current
study is the first to investigate effects of prolonged administration of sub-pressor doses of OT
on AngII-induced hypertension in vivo. We show that OT accelerated AngII-induced hyper-
tension leading to cardiac hypertrophy and, significant damage and compromised function
of the kidneys. These effects were associated with the activation of the calcium-dependent
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calcineurin, a pathological signaling pathway in chronic hypertension. Although we do not
show a direct kidney specific effect, this is the first study to show that OT enhances the acti-
vation of calcineurin by angiotensin II in cardiovascular tissue. OT may contribute to arterial
smooth muscle contraction and hypertension especially in the presence of a pressor agent
like angiotensin II in a manner a kin to OT-mediated contraction of uterine smooth muscle.
Thus, the acceleration of hypertension by OT was a likely a factor contributing to the
increased renal damage. It remains to be determined how our results may relate to the
administration of OT via other routes, apply to other species, or models of chronic hyperten-
sion but, within the confines and limitations of our experimental design, we conclude that
caution should be exercised in the chronic use of OT systemically even at sub-pressor doses
in individuals with pre-existing hypertension.
Supporting Information
S1 File. Starting body weights of experimental rats immediately prior to pump implanta-
tion. Data represent means ± SEM (n = 8). Ang II, Angiotensin II; LDOT, low dose Oxytocin;
HDOT, high dose Oxytocin.
(TIF)
S2 File. Masson's trichrome stained histological sections of the posterior wall of the left
ventricle. Collagen deposition in the posterior wall of the left ventricle was not significantly dif-
ferent between groups treated with saline (control), low dose oxytocin (LDOT), high dose oxy-
tocin (HDOT), angiotensin II (AngII), a combination of angiotensin II and low dose oxytocin
(AngII + LDOT) or angiotensin II and high dose oxytocin (AngII + HDOT) for 28 days. The
original magnification was x100.
(TIF)
S3 File. Masson’s trichrome stained histological sections of the renal cortex and medulla
showing effects of oxytocin on angiotensin II induced renal damage. Pathological changes
in the kidney were scored by histological evaluation of glomerular necrosis, tubular degenera-
tion, necrosis and epithelial sloughing and interstitial fibrosis, and vascular congestion and
extravasation. The original magnification was x100. Measurements were made 28 days follow-
ing the infusion of saline (control), low dose oxytocin (LDOT), high dose oxytocin (HDOT),
angiotensin II (AngII), a combination of angiotensin II and low dose oxytocin (AngII +
LDOT), or angiotensin II and high dose oxytocin (AngII + HDOT).
(TIF)
S4 File. The ARRIVE Guidelines Checklist.
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